Literature DB >> 18815046

Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis.

Merrilee Needham1, Alastair Corbett, Timothy Day, Frank Christiansen, Vicki Fabian, Frank L Mastaglia.   

Abstract

The prevalence of sporadic inclusion body myositis (sIBM) is variable in different populations and ethnic groups. A previous survey in Western Australia in 2000 found a prevalence of 9.3 per million population. We have now performed a follow-up survey to determine whether there has since been any change in prevalence. The current prevalence was found to be 14.9 per million population, with a prevalence of 51.3 per million population in people over 50 years of age. This is the highest reported prevalence of sIBM and correlates with a high frequency of HLA-DR3 and the 8.1 major histocompatibility complex ancestral haplotype in this population. Review of a combined cohort of 57 sIBM cases from three Australian centres revealed a high rate of initial misdiagnosis and a mean time to diagnosis of 5.2 years, which suggests that even the latest prevalence figure may be an underestimate, and emphasising the need to increase the level of awareness of the condition among the medical community.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18815046     DOI: 10.1016/j.jocn.2008.01.011

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  41 in total

Review 1.  Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC.

Authors:  F L Mastaglia
Journal:  Acta Myol       Date:  2009-10

2.  Increase in number of sporadic inclusion body myositis (sIBM) in Japan.

Authors:  Naoki Suzuki; Masashi Aoki; Madoka Mori-Yoshimura; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  J Neurol       Date:  2011-07-29       Impact factor: 4.849

Review 3.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

4.  Dilated cardiomyopathy and inclusion body myositis.

Authors:  Piercarlo Ballo; Leandro Chiodi; Matteo Cameli; Alessandro Malandrini; Antonio Federico; Sergio Mondillo; Alfredo Zuppiroli
Journal:  Neurol Sci       Date:  2011-09-16       Impact factor: 3.307

5.  Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.

Authors:  Karsten Schmidt; Konstanze Kleinschnitz; Goran Rakocevic; Marinos C Dalakas; Jens Schmidt
Journal:  BMC Neurol       Date:  2016-04-16       Impact factor: 2.474

6.  Demographic and clinical features of inclusion body myositis in North America.

Authors:  A David Paltiel; Einar Ingvarsson; Donald K K Lee; Richard L Leff; Richard J Nowak; Kurt D Petschke; Seth Richards-Shubik; Ange Zhou; Martin Shubik; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2015-02-17       Impact factor: 3.217

7.  Investigation of splicing changes and post-translational processing of LMNA in sporadic inclusion body myositis.

Authors:  Yue-Bei Luo; Chalermchai Mitrpant; Russell Johnsen; Vicki Fabian; Merrilee Needham; Sue Fletcher; Steve D Wilton; Frank L Mastaglia
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

Review 8.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 9.  New Developments in the Genetics of Inclusion Body Myositis.

Authors:  Kyla A Britson; Stephanie Y Yang; Thomas E Lloyd
Journal:  Curr Rheumatol Rep       Date:  2018-04-02       Impact factor: 4.592

10.  Vacuolar myopathy in a dog resembling human sporadic inclusion body myositis.

Authors:  Jason King; Richard A LeCouteur; Monica Aleman; D Colette Williams; Peter F Moore; Ling T Guo; Andrew P Mizisin; G Diane Shelton
Journal:  Acta Neuropathol       Date:  2009-08-29       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.